Genital Diseases, Female News

Genital Diseases, Female	Welcome, Profile Billing Logout

«1 2...94 95 96 97 9899100 101 102 103 104...110 111 »

|||||||||| New P2 trial: Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=16, Completed, Sponsor: Endocyte

|||||||||| New P1 trial: Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P1, N=8, Completed, Sponsor: Endocyte

||||||||||  cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases:  Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer (clinicaltrials.gov) -  Sep 19, 2012
P2, N=141, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed

||||||||||  paclitaxel / Generic mfg.
Trial completion:  Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer (clinicaltrials.gov) -  Sep 19, 2012
P2, N=0, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  paclitaxel / Generic mfg.
Trial completion, Surgery, Metastases:  Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva (clinicaltrials.gov) -  Sep 19, 2012
P2, N=31, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  imatinib / Generic mfg.
Trial completion, Metastases:  STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 19, 2012
P2, N=91, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Orathecin (rubitecan) / Vivacitas
Trial completion, Metastases:  Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer (clinicaltrials.gov) -  Sep 19, 2012
P2, N=51, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Metastases:  Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 19, 2012
P2, N=132, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion, Surgery: Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus (clinicaltrials.gov) - Sep 19, 2012
P3, N=224, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  carboplatin / Generic mfg., amifostine / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases:  Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer (clinicaltrials.gov) -  Sep 18, 2012
P2, N=80, Completed,  Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial completion, Metastases:  A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (clinicaltrials.gov) -  Sep 18, 2012
P2, N=19, Completed,  Sponsor: Tyler Curiel
Active, not recruiting --> Completed Terminated --> Completed

|||||||||| New P3 trial, Preclinical: Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF (clinicaltrials.gov) - Sep 17, 2012
P3, N=1106, Recruiting, Sponsor: Finox AG

||||||||||  Ontak (denileukin diftitox) / Eisai, TSD Japan
Enrollment change, Metastases:  Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine (clinicaltrials.gov) -  Sep 17, 2012
P1, N=8, Active, not recruiting,  Sponsor: University of Washington
Terminated --> Completed N=10 --> 8

|||||||||| Trial completion: Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA (clinicaltrials.gov) - Sep 17, 2012
P2, N=33, Completed, Sponsor: Duke University
N=10 --> 8 Active, not recruiting --> Completed

|||||||||| Enrollment change: Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=44, Completed, Sponsor: University of South Florida
Active, not recruiting --> Completed N=320 --> 44

|||||||||| Trial completion: Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=44, Completed, Sponsor: University of South Florida
N=320 --> 44 Recruiting --> Completed

|||||||||| New P1 trial: Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer (clinicaltrials.gov) - Sep 16, 2012
P1, N=12, Completed, Sponsor: Endocyte

|||||||||| Trial termination, Surgery: ExAblate Treatment of Uterine Fibroids for Fertility Enhancement (clinicaltrials.gov) - Sep 12, 2012
P4, N=2, Terminated, Sponsor: InSightec
Recruiting --> Completed Active, not recruiting --> Terminated

|||||||||| Enrollment change, Surgery: ExAblate Treatment of Uterine Fibroids for Fertility Enhancement (clinicaltrials.gov) - Sep 12, 2012
P4, N=2, Terminated, Sponsor: InSightec
Active, not recruiting --> Terminated N=650 --> 2

||||||||||  epacadostat (INCB024360) / Incyte
New P2 trial:  A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy (clinicaltrials.gov) -  Sep 12, 2012
P2, N=110, Recruiting,  Sponsor: Incyte Corporation

||||||||||  Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy:  Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) (clinicaltrials.gov) -  Sep 11, 2012
P3, N=184, Recruiting,  Sponsor: Hoffmann-La Roche

||||||||||  dalantercept (ACE-041) / Merck (MSD)
Trial initiation date:  Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  Sep 10, 2012
P2, N=28, Active, not recruiting,  Sponsor: Gynecologic Oncology Group
N=650 --> 2 Initiation date: Jun 2012 --> Sep 2012

||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases:  Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression (clinicaltrials.gov) -  Sep 10, 2012
P2, N=133, Active, not recruiting,  Sponsor: Eisai Inc.
Initiation date: Jun 2012 --> Sep 2012 Recruiting --> Active, not recruiting

|||||||||| Trial completion, Surgery, Metastases: Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies (clinicaltrials.gov) - Sep 10, 2012
P2, N=50, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment change: Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=33, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed N=176 --> 33

|||||||||| Trial completion: Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=33, Completed, Sponsor: Centers for Disease Control and Prevention
N=176 --> 33 Recruiting --> Completed

|||||||||| Trial completion: Lay Health Advisors for Sexually Transmitted Disease Prevention (clinicaltrials.gov) - Sep 9, 2012
P1/2, N=354, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Recruiting --> Completed

||||||||||  Savella (milnacipran) / AbbVie, Pierre Fabre
Trial completion:  Savella in Treatment for Provoked Vestibulodynia (clinicaltrials.gov) -  Sep 6, 2012
P3, N=31, Completed,  Sponsor: University of Tennessee
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer (clinicaltrials.gov) - Sep 6, 2012
P=N/A, N=17, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=26 --> 17

|||||||||| Trial completion: Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer (clinicaltrials.gov) - Sep 6, 2012
P=N/A, N=17, Completed, Sponsor: City of Hope Medical Center
N=26 --> 17 Active, not recruiting --> Completed

|||||||||| Trial completion: Multi-site Study of Rapid Diagnostic Syphilis Assays (clinicaltrials.gov) - Sep 5, 2012
P=N/A, N=1000, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  birinapant (IGM-9427) / IGM Biosciences
New P2 trial, Metastases:  Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (clinicaltrials.gov) -  Sep 5, 2012
P2, N=11, Completed,  Sponsor: National Cancer Institute (NCI)

|||||||||| Enrollment open: eSiHLE: e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=700, Recruiting, Sponsor: Tulane University Health Sciences Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical:  Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) -  Sep 4, 2012
P=N/A, N=200, Completed,  Sponsor: Assiut University

|||||||||| Clinical: Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=200, Recruiting, Sponsor: Asan Medical Center

|||||||||| Trial completion: Maintaining HIV Prevention Gains in Female Adolescents (clinicaltrials.gov) - Sep 3, 2012
P2, N=640, Completed, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| New P4 trial: OSIPS: Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Aug 28, 2012
P4, N=140, Completed, Sponsor: Mansoura University

|||||||||| Trial completion: Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program (clinicaltrials.gov) - Aug 28, 2012
P0, N=8800, Completed, Sponsor: G
Active, not recruiting --> Completed Enrolling by invitation --> Completed

||||||||||  acyclovir / Generic mfg.
Enrollment change:  Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda (clinicaltrials.gov) -  Aug 27, 2012
P2, N=440, Completed,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Completed N=1320 --> 440

|||||||||| Trial termination: Effect of Cervical Occlusion During Intrauterine Insemination (IUI) (clinicaltrials.gov) - Aug 26, 2012
P3, N=93, Terminated, Sponsor: Women and Infants Hospital of Rhode Island
Recruiting --> Terminated; Randomization flawed. Results were poor in the innovative catheter group

|||||||||| Enrollment change: Effect of Cervical Occlusion During Intrauterine Insemination (IUI) (clinicaltrials.gov) - Aug 26, 2012
P3, N=93, Terminated, Sponsor: Women and Infants Hospital of Rhode Island
Results were poor in the innovative catheter group N=160 --> 93

||||||||||  metformin / Generic mfg.
New P4 trial:  Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women (clinicaltrials.gov) -  Aug 26, 2012
P4, N=90, Recruiting,  Sponsor: Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

|||||||||| Enrollment open: Interactive Educational Website for Women With Ovarian Cancer & Caregivers (clinicaltrials.gov) - Aug 26, 2012
P0, N=200, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=160 --> 93 Not yet recruiting --> Recruiting

|||||||||| Enrollment change, HEOR: Quality-of-Life Assessment in Patients With Ovarian Cancer (clinicaltrials.gov) - Aug 23, 2012
P=N/A, N=372, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting N=280 --> 372

|||||||||| Enrollment open: Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding (clinicaltrials.gov) - Aug 23, 2012
P3, N=312, Recruiting, Sponsor: Bayer
N=280 --> 372 Not yet recruiting --> Recruiting

|||||||||| Trial completion, HEOR: Quality-of-Life Assessment in Patients With Ovarian Cancer (clinicaltrials.gov) - Aug 23, 2012
P=N/A, N=372, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| Metastases: FIRES: Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging (clinicaltrials.gov) - Aug 23, 2012
P=N/A, N=640, Recruiting, Sponsor: Indiana University

||||||||||  goserelin acetate / Generic mfg.
New P4 trial:  The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis. (clinicaltrials.gov) -  Aug 22, 2012
P4, N=120, Recruiting,  Sponsor: AZ Jan Palfijn Gent

||||||||||  azithromycin / Generic mfg.
New P4 trial:  RESCUE: Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) -  Aug 21, 2012
P4, N=400, Enrolling by invitation,  Sponsor: Pfizer

|||||||||| Enrollment change: HX4-200: Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors (clinicaltrials.gov) - Aug 20, 2012
P2, N=50, Completed, Sponsor: Siemens Molecular Imaging
Active, not recruiting --> Completed N=40 --> 50



	Diseases Companies Products Productz Mechanisms of Action Sites